新型减肥药奥利司他的研究进展
作者：马微;付丽;王海波;崔艳妮;蔡天培;于静;唐英章;
Author：
收稿日期： 年卷（期）页码：2009,24(04):-431-433
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：奥利司他;脂酶抑制剂;减肥药;不良反应
Key words：
基金项目：国家科技支撑计划农业领域课题:功能性食品有效成分检测和鉴伪技术的研究(No.2006BAD27B02)
中文摘要
新型抗肥胖药奥利司他是一种胃肠道脂酶抑制剂,能竞争性抑制约1/3摄入脂肪的吸收,除了使体重减轻外,还能降血脂。现简要介绍奥利司他的物理化学性质、合成、检测技术、临床疗效及不良反应。
参考文献
[1]卞红平,宁奇,周后元.奥利司他合成路线图解[J].中国医药工业杂志,2006,37(10):716-720.
[2]Hanessian S,Tehim A,Chen P.Total synthesis of(?)-tetra-hydrolipstatin[J].J Org Chem,1993,58(27):7768-7781.
[3]Barbier P,Schneider F.Syntheses of tetrahydrolipstatin and abso-lute configuration of tetrahydrolipstatin and lipstatin[J].HelvChim Acta,1987,70(1):196-202.
[4]Anne B,Steven RP.Orlistat:its current status as an anti-obesitydrug[J].Euro J Pharmaco,2002,440(1):109-117.
[5]Zhi J,Mulligan TE,Hauptman JB.Long-term systemic expo-sure of orlistat,a lipase inhibitor,and its metabolites in obesepatients[J].Clin Pharmacol,1999,39(1):41-46.
[6]Sjostrom L,Rissanen A,Adersen T,et al.Randomised placebo-controlled trial of orlistat for weight loss and prevention of weightregain in obese patients[J].Lancet,1998,352(9123):167-173.
[7]Davidson MH,Hauptman J,DiGirolamo M,et al.Weight controland risk factor reduction in obese subjects treated for2 years withorlistat.A randomized controlled trial[J].JAMA,1999,281(3):235-242.
[8]王卫庆,宁光,郁忠勤,等.减肥药奥利司他和西布曲明对心血管疾病危险因素及游离睾酮水平的影响[J].上海医药,2002,25(3):176-178.
[9]Hollander PA,Elbein SC,Hirsch IB.Role of orlistat inthe treat-ment of obese patients with type 2 diabetes[J].2Diabetes Care,1998,21(11):1288-1294.
[10]Mohammadia A,Haririan I,Rezanour I,et al.A stability-indica-ting high performance liquid chromatographic assay for the deter-mination of orlistat in capsules[J].Chromato A,2006,1116(1):153-157.
[11]肖松,朱小兰,陈波,等.减肥保健食品中奥利司他的HPLC-UV-ESI-MS的测定[J].卫生研究,2006,35(3):355-357.
[12]Bray GA,Greenway FL.Current and potential drugs for treatmentof obesity[J].Endocr Rev,1999,20(6):805-875.
[13]Finer N,James WP,Kopelman PG,et al.One year treatment of o-besity:a randomi-zed,double blind,placebo controlled,mul-ticentre study of orlistat,a gastrointesti-nal lipase inhibitor[J].Int J Obes Relat Metab Disord,2000,24(3):306-313.
[14]黄世杰.由于致癌危险美国消协要求奥利司他撤出市场[J].国外医学.药学分册,2006,33(5):328.
【关闭】
